Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

The Activin Social Network: Activin, Inhibin, and Follistatin in Breast Development and Cancer.

Seachrist DD, Keri RA.

Endocrinology. 2019 May 1;160(5):1097-1110. doi: 10.1210/en.2019-00015.

PMID:
30874767
2.

The membrane tethered matrix metalloproteinase MT1-MMP triggers an outside-in DNA damage response that impacts chemo- and radiotherapy responses of breast cancer.

Thakur V, Zhang K, Savadelis A, Zmina P, Aguila B, Welford SM, Abdul-Karim F, Bonk KW, Keri RA, Bedogni B.

Cancer Lett. 2019 Feb 28;443:115-124. doi: 10.1016/j.canlet.2018.11.031. Epub 2018 Nov 29.

PMID:
30502358
3.

Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells.

Gayle SS, Sahni JM, Webb BM, Weber-Bonk KL, Shively MS, Spina R, Bar EE, Summers MK, Keri RA.

J Biol Chem. 2019 Jan 18;294(3):875-886. doi: 10.1074/jbc.RA118.004712. Epub 2018 Nov 27.

PMID:
30482844
4.

Expression of LC3B and FIP200/Atg17 in brain metastases of breast cancer.

Hashemi-Sadraei N, Müller-Greven GM, Abdul-Karim FW, Ulasov I, Downs-Kelly E, Burgett ME, Lauko A, Qadan MA, Weil RJ, Ahluwalia MS, Du L, Prayson RA, Chao ST, Budd TG, Barnholtz-Sloan J, Nowacki AS, Keri RA, Gladson CL.

J Neurooncol. 2018 Nov;140(2):237-248. doi: 10.1007/s11060-018-2959-5. Epub 2018 Aug 9.

PMID:
30094720
5.

A breast multi-disciplinary genomic tumor board is feasible and can provide timely and impactful recommendations.

Tsung K, Thompson CL, Knight JM, Maximuk S, Sadri N, Gilmore H, Keri RA, Vinayak S, Harris L, Silverman P.

Breast J. 2018 Jul;24(4):676-677. doi: 10.1111/tbj.13027. Epub 2018 Mar 8. No abstract available.

PMID:
29517142
6.

Targeting bromodomain and extraterminal proteins in breast cancer.

Sahni JM, Keri RA.

Pharmacol Res. 2018 Mar;129:156-176. doi: 10.1016/j.phrs.2017.11.015. Epub 2017 Nov 16. Review.

7.

BETi induction of mitotic catastrophe: towing the LIN9.

Gayle SS, Sahni JM, Keri RA.

Oncoscience. 2017 Oct 23;4(9-10):128-130. doi: 10.18632/oncoscience.372. eCollection 2017 Sep. No abstract available.

8.

Mitotic Vulnerability in Triple-Negative Breast Cancer Associated with LIN9 Is Targetable with BET Inhibitors.

Sahni JM, Gayle SS, Webb BM, Weber-Bonk KL, Seachrist DD, Singh S, Sizemore ST, Restrepo NA, Bebek G, Scacheri PC, Varadan V, Summers MK, Keri RA.

Cancer Res. 2017 Oct 1;77(19):5395-5408. doi: 10.1158/0008-5472.CAN-17-1571. Epub 2017 Aug 14.

9.

Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers.

Morrison CD, Chang JC, Keri RA, Schiemann WP.

Cell Death Dis. 2017 Jun 29;8(6):e2899. doi: 10.1038/cddis.2017.294.

10.

Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer.

Seachrist DD, Sizemore ST, Johnson E, Abdul-Karim FW, Weber Bonk KL, Keri RA.

Breast Cancer Res. 2017 Jun 5;19(1):66. doi: 10.1186/s13058-017-0857-y.

11.

Regulatory cross-talk determines the cellular levels of 53BP1 protein, a critical factor in DNA repair.

Mayca Pozo F, Tang J, Bonk KW, Keri RA, Yao X, Zhang Y.

J Biol Chem. 2017 Apr 7;292(14):5992-6003. doi: 10.1074/jbc.M116.760645. Epub 2017 Mar 2.

12.

Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome.

Cohen AJ, Saiakhova A, Corradin O, Luppino JM, Lovrenert K, Bartels CF, Morrow JJ, Mack SC, Dhillon G, Beard L, Myeroff L, Kalady MF, Willis J, Bradner JE, Keri RA, Berger NA, Pruett-Miller SM, Markowitz SD, Scacheri PC.

Nat Commun. 2017 Feb 7;8:14400. doi: 10.1038/ncomms14400.

13.

Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.

Sahni JM, Gayle SS, Bonk KL, Vite LC, Yori JL, Webb B, Ramos EK, Seachrist DD, Landis MD, Chang JC, Bradner JE, Keri RA.

J Biol Chem. 2016 Nov 4;291(45):23756-23768. Epub 2016 Sep 20.

14.

c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression.

Morrison CD, Allington TM, Thompson CL, Gilmore HL, Chang JC, Keri RA, Schiemann WP.

Oncotarget. 2016 Nov 8;7(45):72777-72794. doi: 10.18632/oncotarget.11909.

15.

Bioengineering of Tobacco Mosaic Virus to Create a Non-Infectious Positive Control for Ebola Diagnostic Assays.

Lam P, Gulati NM, Stewart PL, Keri RA, Steinmetz NF.

Sci Rep. 2016 Mar 31;6:23803. doi: 10.1038/srep23803.

16.

Germline Heterozygous Variants in SEC23B Are Associated with Cowden Syndrome and Enriched in Apparently Sporadic Thyroid Cancer.

Yehia L, Niazi F, Ni Y, Ngeow J, Sankunny M, Liu Z, Wei W, Mester JL, Keri RA, Zhang B, Eng C.

Am J Hum Genet. 2015 Nov 5;97(5):661-76. doi: 10.1016/j.ajhg.2015.10.001. Epub 2015 Oct 29.

17.

A review of the carcinogenic potential of bisphenol A.

Seachrist DD, Bonk KW, Ho SM, Prins GS, Soto AM, Keri RA.

Reprod Toxicol. 2016 Jan;59:167-82. doi: 10.1016/j.reprotox.2015.09.006. Epub 2015 Oct 19. Review.

18.

UbcH7 regulates 53BP1 stability and DSB repair.

Han X, Zhang L, Chung J, Mayca Pozo F, Tran A, Seachrist DD, Jacobberger JW, Keri RA, Gilmore H, Zhang Y.

Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17456-61. doi: 10.1073/pnas.1408538111. Epub 2014 Nov 24.

19.

Combined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression.

Yori JL, Lozada KL, Seachrist DD, Mosley JD, Abdul-Karim FW, Booth CN, Flask CA, Keri RA.

Cancer Res. 2014 Sep 1;74(17):4762-71. doi: 10.1158/0008-5472.CAN-13-3627. Epub 2014 Jul 14.

20.

GABA(A) receptor pi (GABRP) stimulates basal-like breast cancer cell migration through activation of extracellular-regulated kinase 1/2 (ERK1/2).

Sizemore GM, Sizemore ST, Seachrist DD, Keri RA.

J Biol Chem. 2014 Aug 29;289(35):24102-13. doi: 10.1074/jbc.M114.593582. Epub 2014 Jul 10.

21.

Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors.

Sizemore ST, Sizemore GM, Booth CN, Thompson CL, Silverman P, Bebek G, Abdul-Karim FW, Avril S, Keri RA.

Breast Cancer Res Treat. 2014 Jul;146(1):25-40. doi: 10.1007/s10549-014-2989-4. Epub 2014 May 22.

22.

On-command drug release from nanochains inhibits growth of breast tumors.

Peiris PM, Tam M, Vicente P, Abramowski A, Toy R, Bauer L, Mayer A, Pansky J, Doolittle E, Tucci S, Schmidt E, Shoup C, Rao S, Murray K, Gopalakrishnan R, Keri RA, Basilion JP, Griswold MA, Karathanasis E.

Pharm Res. 2014 Jun;31(6):1460-8. doi: 10.1007/s11095-013-1102-8. Epub 2013 Aug 9.

23.

Biodistribution and clearance of a filamentous plant virus in healthy and tumor-bearing mice.

Shukla S, Wen AM, Ayat NR, Commandeur U, Gopalkrishnan R, Broome AM, Lozada KW, Keri RA, Steinmetz NF.

Nanomedicine (Lond). 2014 Feb;9(2):221-35. doi: 10.2217/nnm.13.75. Epub 2013 Jul 9.

24.

FOXC1 is enriched in the mammary luminal progenitor population, but is not necessary for mouse mammary ductal morphogenesis.

Sizemore GM, Sizemore ST, Pal B, Booth CN, Seachrist DD, Abdul-Karim FW, Kume T, Keri RA.

Biol Reprod. 2013 Jul 11;89(1):10. doi: 10.1095/biolreprod.113.108001. Print 2013 Jul.

25.

The HER2- and heregulin β1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression.

Asrani K, Keri RA, Galisteo R, Brown SA, Morgan SJ, Ghosh A, Tran NL, Winkles JA.

Mol Cancer Res. 2013 Apr;11(4):393-404. doi: 10.1158/1541-7786.MCR-12-0542. Epub 2013 Feb 1.

26.

Imaging metastasis using an integrin-targeting chain-shaped nanoparticle.

Peiris PM, Toy R, Doolittle E, Pansky J, Abramowski A, Tam M, Vicente P, Tran E, Hayden E, Camann A, Mayer A, Erokwu BO, Berman Z, Wilson D, Baskaran H, Flask CA, Keri RA, Karathanasis E.

ACS Nano. 2012 Oct 23;6(10):8783-95. doi: 10.1021/nn303833p. Epub 2012 Sep 24.

27.

Overexpression of follistatin in the mouse epididymis disrupts fluid resorption and sperm transit in testicular excurrent ducts.

Seachrist DD, Johnson E, Magee C, Clay CM, Graham JK, Veeramachaneni DN, Keri RA.

Biol Reprod. 2012 Aug 23;87(2):41. doi: 10.1095/biolreprod.111.097527. Print 2012 Aug.

28.

The forkhead box transcription factor FOXC1 promotes breast cancer invasion by inducing matrix metalloprotease 7 (MMP7) expression.

Sizemore ST, Keri RA.

J Biol Chem. 2012 Jul 13;287(29):24631-40. doi: 10.1074/jbc.M112.375865. Epub 2012 May 29.

29.

Enhanced delivery of chemotherapy to tumors using a multicomponent nanochain with radio-frequency-tunable drug release.

Peiris PM, Bauer L, Toy R, Tran E, Pansky J, Doolittle E, Schmidt E, Hayden E, Mayer A, Keri RA, Griswold MA, Karathanasis E.

ACS Nano. 2012 May 22;6(5):4157-68. doi: 10.1021/nn300652p. Epub 2012 Apr 13.

30.

FOXA1 represses the molecular phenotype of basal breast cancer cells.

Bernardo GM, Bebek G, Ginther CL, Sizemore ST, Lozada KL, Miedler JD, Anderson LA, Godwin AK, Abdul-Karim FW, Slamon DJ, Keri RA.

Oncogene. 2013 Jan 31;32(5):554-63. doi: 10.1038/onc.2012.62. Epub 2012 Mar 5.

31.

FOXA1: a transcription factor with parallel functions in development and cancer.

Bernardo GM, Keri RA.

Biosci Rep. 2012 Apr 1;32(2):113-30. doi: 10.1042/BSR20110046. Review.

PMID:
22115363
32.

Myosin II isoform switching mediates invasiveness after TGF-β-induced epithelial-mesenchymal transition.

Beach JR, Hussey GS, Miller TE, Chaudhury A, Patel P, Monslow J, Zheng Q, Keri RA, Reizes O, Bresnick AR, Howe PH, Egelhoff TT.

Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):17991-6. doi: 10.1073/pnas.1106499108. Epub 2011 Oct 24.

33.

Krüppel-like factor 4 inhibits tumorigenic progression and metastasis in a mouse model of breast cancer.

Yori JL, Seachrist DD, Johnson E, Lozada KL, Abdul-Karim FW, Chodosh LA, Schiemann WP, Keri RA.

Neoplasia. 2011 Jul;13(7):601-10.

34.

Bisphenol A increases mammary cancer risk in two distinct mouse models of breast cancer.

Weber Lozada K, Keri RA.

Biol Reprod. 2011 Sep;85(3):490-7. doi: 10.1095/biolreprod.110.090431. Epub 2011 Jun 2.

35.

Aberrant expression of LMO4 induces centrosome amplification and mitotic spindle abnormalities in breast cancer cells.

Montañez-Wiscovich ME, Shelton MD, Seachrist DD, Lozada KL, Johnson E, Miedler JD, Abdul-Karim FW, Visvader JE, Keri RA.

J Pathol. 2010 Nov;222(3):271-81. doi: 10.1002/path.2762.

36.

HER2/ErbB2-induced breast cancer cell migration and invasion require p120 catenin activation of Rac1 and Cdc42.

Johnson E, Seachrist DD, DeLeon-Rodriguez CM, Lozada KL, Miedler J, Abdul-Karim FW, Keri RA.

J Biol Chem. 2010 Sep 17;285(38):29491-501. doi: 10.1074/jbc.M110.136770. Epub 2010 Jul 1.

37.

FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis.

Bernardo GM, Lozada KL, Miedler JD, Harburg G, Hewitt SC, Mosley JD, Godwin AK, Korach KS, Visvader JE, Kaestner KH, Abdul-Karim FW, Montano MM, Keri RA.

Development. 2010 Jun;137(12):2045-54. doi: 10.1242/dev.043299.

38.

Kruppel-like factor 4 inhibits epithelial-to-mesenchymal transition through regulation of E-cadherin gene expression.

Yori JL, Johnson E, Zhou G, Jain MK, Keri RA.

J Biol Chem. 2010 May 28;285(22):16854-63. doi: 10.1074/jbc.M110.114546. Epub 2010 Mar 31.

39.

LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression.

Montañez-Wiscovich ME, Seachrist DD, Landis MD, Visvader J, Andersen B, Keri RA.

Oncogene. 2009 Oct 15;28(41):3608-18. doi: 10.1038/onc.2009.221. Epub 2009 Aug 3.

40.

Intrinsic bias in breast cancer gene expression data sets.

Mosley JD, Keri RA.

BMC Cancer. 2009 Jun 29;9:214. doi: 10.1186/1471-2407-9-214.

41.

The double-stranded RNA-binding protein, PACT, is required for postnatal anterior pituitary proliferation.

Peters GA, Seachrist DD, Keri RA, Sen GC.

Proc Natl Acad Sci U S A. 2009 Jun 30;106(26):10696-701. doi: 10.1073/pnas.0900735106. Epub 2009 Jun 17.

42.

Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists.

Mosley JD, Keri RA.

BMC Med Genomics. 2008 Apr 25;1:11. doi: 10.1186/1755-8794-1-11.

43.

Ovarian hyperstimulation induces centrosome amplification and aneuploid mammary tumors independently of alterations in p53 in a transgenic mouse model of breast cancer.

Milliken EL, Lozada KL, Johnson E, Landis MD, Seachrist DD, Whitten I, Sutton AL, Abdul-Karim FW, Keri RA.

Oncogene. 2008 Mar 13;27(12):1759-66. Epub 2007 Sep 24.

44.

Chapel Hill bisphenol A expert panel consensus statement: integration of mechanisms, effects in animals and potential to impact human health at current levels of exposure.

vom Saal FS, Akingbemi BT, Belcher SM, Birnbaum LS, Crain DA, Eriksen M, Farabollini F, Guillette LJ Jr, Hauser R, Heindel JJ, Ho SM, Hunt PA, Iguchi T, Jobling S, Kanno J, Keri RA, Knudsen KE, Laufer H, LeBlanc GA, Marcus M, McLachlan JA, Myers JP, Nadal A, Newbold RR, Olea N, Prins GS, Richter CA, Rubin BS, Sonnenschein C, Soto AM, Talsness CE, Vandenbergh JG, Vandenberg LN, Walser-Kuntz DR, Watson CS, Welshons WV, Wetherill Y, Zoeller RT.

Reprod Toxicol. 2007 Aug-Sep;24(2):131-8. Epub 2007 Jul 27. No abstract available.

45.

The pleiotropic effects of excessive luteinizing hormone secretion in transgenic mice.

Sutton AL, Keri RA.

Semin Reprod Med. 2007 Sep;25(5):360-7. Review.

PMID:
17710732
46.

An evaluation of evidence for the carcinogenic activity of bisphenol A.

Keri RA, Ho SM, Hunt PA, Knudsen KE, Soto AM, Prins GS.

Reprod Toxicol. 2007 Aug-Sep;24(2):240-52. Epub 2007 Jun 28. Review.

47.
48.

Increases in luteinizing hormone are associated with declines in cognitive performance.

Casadesus G, Milliken EL, Webber KM, Bowen RL, Lei Z, Rao CV, Perry G, Keri RA, Smith MA.

Mol Cell Endocrinol. 2007 Apr 15;269(1-2):107-11. Epub 2007 Feb 6.

PMID:
17376589
49.

Splice variants of mIAP1 have an enhanced ability to inhibit apoptosis.

Mosley JD, Keri RA.

Biochem Biophys Res Commun. 2006 Sep 29;348(3):1174-83. Epub 2006 Aug 4.

50.

Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors.

Landis MD, Seachrist DD, Abdul-Karim FW, Keri RA.

Oncogene. 2006 Jun 1;25(23):3325-34. Epub 2006 Jan 23.

Supplemental Content

Support Center